• PDHA1 Succinylation, α-KGA, and Cholangiocarcinoma

  2026-08-22

  A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic switch that increases α-ketoglutaric acid in the cholangiocarcinoma microenvironment. The resulting OXGR1–MAPK signal suppresses macrophage MHC-II antigen presentation, while inhibiting succinylation with CPI-613 may improve gemcitabine–cisplatin sensitivity.

• Sanggenol L Drives Ferroptosis in NSCLC via miRNA–p53

  2026-08-21

  The reference study identifies sanggenol L as an inducer of ferroptosis in non-small cell lung cancer (NSCLC) and connects this effect to the miR-26a-1-3p/MDM2/p53/SLC7A11 regulatory axis. Its combination of molecular perturbation, ferroptosis-associated readouts, xenograft studies, and patient-derived tumor xenografts provides a mechanistic framework for evaluating natural-product strategies against NSCLC.

• From PS Exposure to Translational Apoptosis Insight

  2026-08-20

  A mechanistic and strategic guide to using the Annexin V-Cy5/DAPI Apoptosis Kit to connect phosphatidylserine exposure with P2RX1-driven mitochondrial apoptosis, tyrosine kinase inhibitor response, and more rigorous translational decision-making in Ph+ ALL research.

• 5-Azacytidine Workflow for Cancer Epigenetics

  2026-08-20

  Build reproducible 5-Azacytidine assays that connect DNMT inhibition with gene reactivation, cytotoxicity, and cancer-cell dormancy. This workflow translates the AZA–retinoic acid findings from a metastasis study into practical dose, timing, control, and troubleshooting decisions.

• Cefepime (BMY-28142) in Resistance Models

  2026-08-19

  Cefepime (BMY-28142) supports a practical bridge between β-lactam susceptibility testing, plasmid-mediated resistance analysis, and central nervous system infection research. This guide shows how to build reproducible assays while treating resistance, blood-brain barrier exposure, and neurotoxicity as separate experimental questions.

• 5-Azacytidine: DNMT Inhibitor for Cancer Research

  2026-08-19

  5-Azacytidine, also called 5-AzaC, is a cytosine analogue DNA methyltransferase inhibitor used to study DNA demethylation, gene reactivation, and cancer-cell responses. Its mechanism depends on nucleic-acid incorporation and DNMT trapping, while recent work shows that combination treatment with retinoic-acid agonists can reprogram disseminated cancer cells into dormancy.

• CFDA SE Cell Tracer Kit: Practical Workflow

  2026-08-18

  The CFDA SE Cell Tracer Kit provides stable fluorescent labeling for cell lineage tracing, cell proliferation studies, and related flow cytometry or microscopy workflows. It is intended for persistent covalent tracking over several days, not for short-term reversible labeling or rapid real-time dye-clearance studies.

• Biotin-tyramide (A8011): Practical TSA Guide

  2026-08-18

  Biotin-tyramide (A8011) supports HRP-driven biotin deposition when conventional immunohistochemistry or in situ hybridization signals are too weak for reliable imaging. It is intended for fixed cells and tissue sections in research workflows, not as a general water-soluble labeling reagent or for diagnostic and medical use.

• Cy3 Goat Anti-Rabbit IgG: From Biomarker to Image

  2026-08-17

  Discover how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody can connect quantitative HMGB1 biomarker discovery with spatial validation in immunofluorescence, IHC, and ICC. This evidence-driven guide focuses on assay architecture, controls, signal interpretation, and practical limitations rather than routine product promotion.

• HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation

  2026-08-17

  The reference study identifies an LMP1–STAT5A–HDAC1/2–CEBPA pathway through which Epstein–Barr virus promotes dedifferentiation and plasticity in nasopharyngeal carcinoma. Its experiments support HDAC inhibition as a differentiation-oriented strategy for restoring CEBPA activity and reducing stem-like tumor-cell states in xenograft models.

• CHIR-99021 for Mesodermal Organoid Signaling

  2026-08-16

  CHIR-99021 (CT99021) gives stem cell and organoid researchers a tunable way to interrogate GSK-3–dependent Wnt signaling, lineage commitment, and tissue organization. This workflow connects a defined small-molecule pulse with the budoid model’s epithelial–mesodermal signaling logic, while providing practical controls for dose, timing, stock handling, and morphological variability.

• EdU Imaging Kits (Cy3): S-Phase DNA Detection

  2026-08-15

  EdU Imaging Kits (Cy3) provide a 5-ethynyl-2'-deoxyuridine imaging kit workflow for labeling nascent DNA without antibody-based DNA denaturation. The Cy3 click-chemistry readout supports fluorescence microscopy, flow cytometry, and controlled cell proliferation or genotoxicity studies.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Assay Strategy

  2026-08-14

  Learn how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody supports mechanistically rigorous immunofluorescence, IHC, and ICC workflows. This guide connects reagent selection with pathway-level interpretation using recent rheumatoid arthritis research as a practical model.

• A-1331852: BCL-XL Inhibition in Glioblastoma

  2026-08-14

  A-1331852 is a selective BCL-XL inhibitor for dissecting apoptotic dependence in glioblastoma and other cancer models. This article connects BCL-XL–BIM complex disruption with apoptotic priming, assay design, and translational limitations.

• Podophyllotoxin Workflows for HCC and Autophagy

  2026-08-13

  Build reproducible Podophyllotoxin assays around microtubule disruption, G2/M arrest, apoptosis, and autophagy flux. This guide distinguishes direct compound testing from mechanistically related hepatocellular carcinoma research and provides practical preparation, optimization, and troubleshooting strategies.

5562 records 1/371 page Next 12345 下5页 Last page